11月28日正式交易！恒生医药板块唯一期指来了

Core Viewpoint - The launch of the Hang Seng Biotechnology Index futures on November 28, 2025, marks a significant enhancement in the investment landscape of the biotechnology sector in Hong Kong, indicating the industry's growing importance in thematic investments [1][2]. Group 1: Index Futures Launch - The Hang Seng Biotechnology Index futures will officially trade starting November 28, 2025, with the underlying asset being the Hang Seng Medicine ETF (159892) [1]. - This product is the first new index futures in Hong Kong's stock market in five years, reflecting the increasing prominence of the pharmaceutical industry [1]. - The introduction of this futures product enriches the range of derivative products in the Hang Seng Index series and strengthens the risk management and capital allocation capabilities of the biotechnology sector [1][3]. Group 2: Investment Value in Biotechnology - The Hang Seng Biotechnology Index focuses on 30 leading biotechnology companies listed in Hong Kong, capturing the core development trends of the industry [2]. - As of November 25, 2025, the index has seen an annual increase of over 80%, significantly outperforming the Hang Seng Composite Index [2]. - The biotechnology sector is supported by long-term trends such as an aging population and increasing medical demands, which continue to open up growth opportunities [2]. Group 3: Derivative Tools and Market Dynamics - The introduction of the Hang Seng Biotechnology Index futures serves as a crucial risk management tool for the high-growth and high-volatility characteristics of the biotechnology sector [3]. - Similar index derivatives have shown strong market vitality, with the Hang Seng Technology Index futures experiencing a 31% increase in average daily trading volume in the first three quarters of 2025 compared to the previous year [3]. - The collaboration between index futures and ETFs is expected to optimize the capital ecosystem of the biotechnology industry, attracting institutional investors and enhancing liquidity and pricing efficiency [4]. Group 4: Future Prospects - The launch of the Hang Seng Biotechnology Index futures is anticipated to promote the deep integration of innovative resources and capital markets in the biotechnology field, supporting long-term healthy development of the industry [4].